3 results about "APOPTOGENIC PROTEIN" patented technology

The present application relates to the technical field of renal cell carcinoma, and particularly relates to a method for predicting the lipid metabolism regulation mechanism of renal cell carcinoma, which is characterized by the following steps: determining the expression difference of EMT, cell proliferation and apoptosis proteins in groups through molecular detection, and determining the difference of fat pathway genes, oil accumulation degree and fat factor expression level in groups, and determining the correlation between lipid metabolism and GAD2, the present project first proposes the miR-metabolic enzyme-lipid pool regulation axis, which is different from the traditional mode of miR directly targeting proliferation genes. Previous studies have focused on the regulation of miRNA on directly related genes such as tumor cell proliferation and apoptosis, and the present project starts from the fat metabolism pathway and deeply explores the regulation of miR-362-5p targeting GAD2 gene on the progression of renal cell carcinoma (RCC). This innovation provides a new perspective and theoretical framework for RCC research, and is expected to open up a new treatment idea, and a systematic research system from clinical samples, cell experiments, molecular detection to animal experiments is constructed.

Provides a structurally stabilized and / or cysteine-reactive NOXA peptide. [Solution] This disclosure relates to a structurally stabilizing and / or cysteine-reactive NOXA BH3 peptide that can covalently bind to BFL-1 and can also bind to BFL-1 and / or MCL-1 by non-covalent interactions. This disclosure also features methods for using such peptides alone or in combination with other therapeutic agents (e.g., inhibitors of DNA damage response pathway members (e.g., ATM kinase inhibitors, ATR kinase inhibitors, CHK1 / 2 inhibitors, PARP inhibitors), selective inhibitors of MCL-1, selective inhibitors of BCL-2, inhibitors of BCL-2 / BCL-XL) in the treatment of BFL-1 and / or MCL-1-dependent or MCL-1-expressing cancers (e.g., hematopoietic malignancies, melanoma).